MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

SkyePharma PLC Company Profile (NASDAQ:SKYEY)

Consensus Ratings for SkyePharma PLC (NASDAQ:SKYEY) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for SkyePharma PLC (NASDAQ:SKYEY)
No equities research coverage for this company has been tracked by

Earnings History for SkyePharma PLC (NASDAQ:SKYEY)
No earnings announcements for this company have been tracked by

Earnings Estimates for SkyePharma PLC (NASDAQ:SKYEY)
No earnings estimates for this company have been tracked by

Dividend History for SkyePharma PLC (NASDAQ:SKYEY)
No dividend announcements for this company have been tracked by

Insider Trading History for SkyePharma PLC (NASDAQ:SKYEY)
No insider trades for this company have been tracked by

Latest Headlines for SkyePharma PLC (NASDAQ:SKYEY)
06/02/16 03:18 PMSkyePharma Plc : Neutral assessment on price but strong on fundamentals -
03/21/16 01:35 PMSkyePharma Plc :SKYEY-US: Earnings Analysis: For the six months ended December 31, 2015 -
03/21/16 10:59 AMSkyePharma Plc :SKYEY-US: Earnings Analysis: 2015 By the Numbers -
01/28/16 01:25 AMMundipharma Appointed as Development and Marketing Partner for flutiform(R) in Mexico, Central and South America - [PR Newswire] - SINGAPORE, Jan. 28, 2016 /PRNewswire/ -- Mundipharma International Corporation Limited has announced that it has entered into agreements with Skyepharma PLC (LSE SKP), the expert oral and inhalation drug development company, and Sanofi Winthrop Industrie ("Sanofi") to transfer the exclusive development, licensing and marketing rights for flutiform® for Mexico, Central and South America ("Territory") to the Mundipharma network of independent associated companies ("Mundipharma"). Mundipharma already has exclusive development, licensing and marketing rights for flutiform® in most markets outside Japan and the Americas. flutiform®, the novel combination of the fast-acting long-acting beta agonist (LABA), formoterol, and the most widely prescribed inhaled corticosteroid (ICS), fluticasone, has been launched and is being marketed successfully by Mundipharma in 29 countries and Mundipharma now intends to leverage this experience in the Territory.
01/07/16 03:09 PMSkyePharma Plc : Overvalued relative to peers, but may deserve another look -
10/28/15 12:55 PMSkyePharma Plc – Value Analysis (US OTC:SKYEY) : October 28, 2015 -
About SkyePharma PLC

SkyePharma PLC logoSkyepharma PLC (Skyepharma) is a specialty pharmaceutical company. The Company is engaged in the development and delivery of oral and inhalation pharmaceutical products. The Company's products pipeline includes four inhalation products, 10 oral products, one topical product and one injectable product. The Company's products include flutiform, Exparel, Paxil CR, Sular, Diclofenacratiopharm, Madopar DR and Coruno, among others. The Company's product flutiform is a multi-dose pressurized metered dose inhaler, utilizing SkyeDry technology, containing steroid (fluticasone) and a beta agonist (formoterol). flutiform is indicated for the treatment of asthma. Exparel is a bupivacaine injectable product indicated for post-surgical pain management. The Product utilizes Pacira Pharmaceuticals' DepoFoam technology. The Company has approximately 10 approved oral products that are sold in over 80 countries.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SKYEY
  • CUSIP:
Key Metrics:
  • Previous Close: $6.28
  • 50 Day Moving Average: $6.62
  • 200 Day Moving Average: $6.01
  • P/E Ratio: 17.35
  • P/E Growth: 0.00
  • Market Cap: $657.57M
  • Current Quarter EPS Consensus Estimate: $N/A EPS
Additional Links:
SkyePharma PLC (NASDAQ:SKYEY) Chart for Friday, July, 1, 2016

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha